Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

NCT00039182 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Mesothelioma
Epithelial Mesothelioma
Recurrent Malignant Mesothelioma
Sarcomatous Mesothelioma

Interventions

DRUG: erlotinib hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)